Strengthening the sustainability of neglected tropical disease programs in Rwanda: An assessment of access and utilization of domestically-financed services for soil-transmitted helminthiases and schistosomiasis

The most available drugs were mebendazole, with 100% of facilities reporting no stockout. Praziquantel (PZQ) was the most unavailable drug, reporting 92% stockout at the time of the survey, mainly due to delays in getting supplies from MDA-implementing health facilities. Diagnostics for SCH are the most inaccessible lab services. On average, the total cost (both direct and opportunity cost) to access and utilize STH and SCH services was USD 0.72 (RWF 861.92) and USD 0.96 (RWF 1136.41) for male and female patients, respectively. Although the assessment revealed that treatment for STH and SCH was affordable for the LPGW, women pay a 33% higher cost than men to access NTD services. While services are generally satisfactory, the reimbursement processes are slow, hindering timely access and utilization of SCH and STH services at the health facilities in Rwanda. While the access and utilization of STH and SCH services in health centers are generally promising, the findings underscore the potential for improvement. By addressing the efficiency in the supply of praziquantel drugs and enhancing reimbursement timelines, we can ensure the continuity and effectiveness of these services, offering hope for a brighter future in the fight against neglected tropical diseases.